Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX-105 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PRX-105 | DRUG | Sterile solution for intravenous injection |
PRX-105 is being developed for organophosphate exposure, a condition that falls within the infectious disease therapeutic area. It is an investigational small molecule from Protalix BioTherapeutics and has been studied in an early Phase 1 microdose trial. It is not an approved product.
PRX-105 targets acetylcholinesterase, an enzyme. By acting on this enzyme target, the small molecule is designed for use in organophosphate exposure. The acetylcholinesterase enzyme is the molecular target identified for this investigational candidate.
PRX-105 is being developed by Protalix BioTherapeutics, Inc., which trades under the ticker PLX. The company is the sponsor behind the organophosphate exposure program for this small molecule candidate.
PRX-105 is in Phase 1 development. Its only recorded trial is an exploratory Phase 1 microdose study that has been completed. The drug remains investigational and is not approved for any indication.
PRX-105 has been studied in one clinical trial, NCT01093859, titled An Exploratory Phase 1 Microdose Study of PRX-105. The trial enrolled 10 participants, was uncontrolled, and is now completed. No active trials of PRX-105 are currently listed.